FKBP5 blockade may provide a new horizon for the treatment of stress‐associated disorders: An in‐silico study

OBJECTIVE: We searched for, from the FDA (Food and Drug Administration‐USA)‐approved drugs, inhibitors of FKBP5 with tolerable adverse effect profiles (eg, mild headache, sedation, etc.) and with the ability to cross the blood brain barrier (BBB), using bio‐informatics tools (in‐silico). This may pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Asadi‐Pooya, Ali A., Malekpour, Mahdi, Zamiri, Bardia, Kashkooli, Mohammad, Firouzabadi, Negar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10235572/
https://www.ncbi.nlm.nih.gov/pubmed/37078238
http://dx.doi.org/10.1002/epi4.12749

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10235572/
https://www.ncbi.nlm.nih.gov/pubmed/37078238
http://dx.doi.org/10.1002/epi4.12749

Ejemplares similares